Clinical Research Associates, LLC (CRA) is an affiliate of the Simons Foundation. The goals of CRA are to better understand the causes of autism spectrum disorder (ASD), accelerate translational and clinical research, and improve the lives of individuals with ASD and related conditions.

CRA’s immediate aim is to evaluate arbaclofen (R-baclofen, STX209), an experimental medication, as a potential therapy in ASD and related conditions. CRA holds the intellectual property for such uses of arbaclofen.

CRA welcomes applications from qualified investigators to request supplies of arbaclofen for use in animal studies or human research. Please contact [email protected] with such requests, or for other questions related to arbaclofen.

Clinical Research Associates, LLC (CRA) has partnered with researchers in the European Union to better understand the safety and efficacy of arbaclofen in children and adolescents with autism (clinical trial NCT03682978). CRA is committed to protecting the privacy of participants in this study and their data. If you have any concerns about the privacy of your data, please email [email protected].